The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Market Overview

• The montelukast sodium market has seen strong growth, increasing from $3.52 billion in 2023 to $3.86 billion in 2024 at a CAGR of 9.6%.
• Expected to continue growing, the market will reach $5.59 billion in 2028 at a CAGR of 9.7%.
• Historic growth factors: increasing respiratory disorders, aging population, rising air pollution, growing awareness, and expansion in emerging markets.
• Future growth drivers: approval and launch of new drugs, clinical studies, patent expiries, regulatory changes, and physician prescribing patterns.

Rising Prevalence of Asthma

• Asthma prevalence is a significant driver for the montelukast sodium market.
• Asthma causes inflammation and constriction of the airways, leading to symptoms like wheezing and breathlessness.
• Contributing factors: environmental pollution, allergen exposure, genetic predisposition, urbanization, lifestyle changes, and respiratory infections.
• Montelukast sodium helps manage asthma symptoms by blocking leukotrienes.
• Example: National Health Service reported a 149% increase in hospital admissions for children with asthma in England and Wales from 2021 to 2022, indicating the growing need for asthma treatments.

View More On The Montelukast Sodium Market Report 2024 – https://www.thebusinessresearchcompany.com/report/montelukast-sodium-global-market-report

Key Market Players

• Major companies: Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Intas Pharmaceuticals Ltd., Seqens Group, Sanyo Chemical Industries Ltd., Morepen Laboratories, Neuland Laboratories Ltd., Medopharm Private Ltd., BEC Chemicals Pvt. Ltd, Delmar Chemicals Inc., Kimia Biosciences Ltd., Ortin Laboratories Ltd., MSN Laboratories Pvt Ltd., Vamsi Labs Ltd., LGM Pharma LLC, HRV Global Life Sciences, Sigmak Lifesciences, Akums Lifesciences Ltd., Anwita Drugs & Chemicals Pvt Ltd.

Introduction of New Anti-Allergy Treatments

• Companies are expanding their portfolios by developing and gaining approval for new drugs, such as fexofenadine hydrochloride.
• Fexofenadine hydrochloride: a second-generation antihistamine for allergy symptoms and hay fever.
• Example: In December 2021, Morepen Laboratories received USFDA approval to market generic fexofenadine hydrochloride in the US, enhancing its anti-allergy market position.

Strategic Acquisitions

• Example: In April 2023, SK Capital Partners acquired Apotex Pharmaceutical Holdings Inc.
• This acquisition enhances SK Capital’s presence in the pharmaceutical industry, providing access to Apotex’s global operations, product portfolio, and workforce.

Market Segmentation

• By Product: Crystal-like, Form-less Or Amorphous
• By Dosage Form: Tablets, Oral Solutions
• By Application: Bronchospasm, Allergic Coryza, Asthma, Urticaria, Other Applications

Regional Insights

• North America was the largest market for montelukast sodium in 2023.
• Asia-Pacific is expected to be the fastest-growing region during the forecast period.

Conclusion

• The montelukast sodium market is poised for continued robust growth due to increasing asthma prevalence, strategic acquisitions, new drug introductions, and regional expansion.
• Companies are well-positioned to capitalize on emerging trends and opportunities in this dynamic market.

Request A Sample Of The Global Montelukast Sodium Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16123&type=smp